In final draft guidance published today NICE has confirmed its earlier positive draft decision recommending rivaroxaban (Xarelto, Bayer Healthcare), in combination with clopidogrel and aspirin, or with aspirin alone, as an option
23 January 2015
NICE has issued further draft guidance which recommends empagliflozin, marketed by Boehringer Ingelheim, for treating type 2 diabetes.
22 January 2015
An updated briefing to help local authorities and partner organisations tackle tobacco use is published today (Wednesday 21 January).
21 January 2015
NICE is consulting on draft recommendations to help people strike the right balance when it comes to being out in the sun.
20 January 2015